Helaina, a NYC-based biotechnology company developing human equivalent bioactive proteins, raised $45M in Series B funding.
The round, which brought the total amount to $83M, was led by Avidity Partners, with additional investment from Spark Capital, Ingeborg Investments, Tom Williams of Heron Rock, Barrel Ventures, Siam Capital, Relish Works, CF Private Equity and Primary Venture Partners, among other strategic partners.
The company intends to use the funds to scale the availability of effera™Human Lactoferrin, a novel ingredient to support women’s health, active nutrition and healthy aging.
Led by CEO and Founder Laura Katz, Helaina is a biotechnology company aiming to transform nutrition with human equivalent bioactive proteins. Developed with its precision fermentation platform, it is selling effera™ to consumer brands and through strategic distribution partners; it will soon be available in consumer products, including from Kroma Wellness, The Feed, Levelle Nutrition and Healthgevity and via the distributor Mitsubishi International Food Ingredients, Inc.
FinSMEs
25/09/2024